Soluble IL-1RII and IL-18 are associated with incipient upper extremity soft tissue disorders

Cytokine

Volumn 54, Issue 2, 2011, Pages 149-153

  Rechardt, Martti ^a   Shiri, Rahman ^a   Matikainen, Sampsa ^a   Viikari Juntura, Eira ^a   Karppinen, Jaro ^a,b   Alenius, Harri ^a  

^a FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

Body mass index; Cytokine receptors; Interleukin 1; Musculoskeletal disorders; Upper extremity

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARM DISEASE; ARTICLE; BODY MASS; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; LIMB PAIN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RISK FACTOR; SHOULDER IMPINGEMENT SYNDROME; SLEEP DISORDER; SOFT TISSUE DISEASE; TENNIS ELBOW;

ADULT; CASE-CONTROL STUDIES; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; INTERLEUKIN-18; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1 TYPE II; SOLUBILITY; UPPER EXTREMITY;

EID: 79953042821     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.02.003     Document Type: Article

References (15)

1. Silverstein B., Viikari-Juntura E., Kalat J. Use of a prevention index to identify industries at high risk for work-related musculoskeletal disorders of the neck, back, and upper extremity in Washington state, 1990-1998. Am J Ind Med 2002, 41:149-169.
2. Walker-Bone K., Palmer K.T., Reading I., Coggon D., Cooper C. Prevalence and impact of musculoskeletal disorders of the upper limb in the general population. Arthritis Rheum 2004, 51:642-651.
3. Shiri R., Varonen H., Heliovaara M., Viikari-Juntura E. Hand dominance in upper extremity musculoskeletal disorders. J Rheumatol 2007, 34:1076-1082.
4. van Rijn R.M., Huisstede B.M., Koes B.W., Burdorf A. Associations between work-related factors and the carpal tunnel syndrome - a systematic review. Scand J Work Environ Health 2009, 35:19-36.
5. Viikari-Juntura E., Shiri R., Solovieva S., Karppinen J., Leino-Arjas P., Varonen H., et al. Risk factors of atherosclerosis and shoulder pain - is there an association? A systematic review. Eur J Pain 2008, 12:412-426.
6. Cannon J.G., St Pierre B.A. Cytokines in exertion-induced skeletal muscle injury. Mol Cell Biochem 1998, 179:159-167.
7. Barbe M.F., Barr A.E. Inflammation and the pathophysiology of work-related musculoskeletal disorders. Brain Behav Immun 2006, 20:423-429.
8. Wang J.H. Mechanobiology of tendon. J Biomech 2006, 39:1563-1582.
9. Barbe M.F., Elliott M.B., Abdelmagid S.M., Amin M., Popoff S.N., Safadi F.F., et al. Serum and tissue cytokines and chemokines increase with repetitive upper extremity tasks. J Orthop Res 2008, 26:1320-1326.
10. Gotoh M., Hamada K., Yamakawa H., Yanagisawa K., Nakamura M., Yamazaki H., et al. Interleukin-1-induced subacromial synovitis and shoulder pain in rotator cuff diseases. Rheumatology (Oxford) 2001, 40:995-1001.
11. Carp S.J., Barbe M.F., Winter K.A., Amin M., Barr A.E. Inflammatory biomarkers increase with severity of upper-extremity overuse disorders. Clin Sci (Lond) 2007, 112:305-314.
12. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
13. Shao X.T., Feng L., Gu L.J., Wu L.J., Feng T.T., Yang Y.M., et al. Expression of interleukin-18, IL-18BP, and IL-18R in serum, synovial fluid, and synovial tissue in patients with rheumatoid arthritis. Clin Exp Med 2009, 9:215-221.
14. Osborn O., Gram H., Zorrilla E.P., Conti B., Bartfai T. Insights into the roles of the inflammatory mediators IL-1, IL-18 and PGE2 in obesity and insulin resistance. Swiss Med Wkly 2008, 138:665-673.
15. van Leeuwen W.M., Lehto M., Karisola P., Lindholm H., Luukkonen R., Sallinen M., et al. Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP. PLoS One 2009, 4:e4589.